CheckMate 914 Fails To Demonstrate Adjuvant Nivolumab–Ipilimumab Benefit For High-Risk RCC
From ESMO Congress 2022:
Nivolumab plus ipilimumab after nephrectomy does not extend disease-free survival for high-risk patients with renal cell carcinoma
Congress Scientific Watch
The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.
Login to start reading, or Join ESMO - All articles are Open Access after 6 months.
55 results
STAMPEDE: No Additional mHSPC Benefit With Enzalutamide
From ESMO Congress 2022:
Use of enzalutamide alongside abiraterone plus steroids and androgen deprivation therapy does not further improve overall survival of metastatic hormone-sensitive prostate cancer
First-Line Camrelizumab Plus Rivoceranib Regimen ‘Supported’ For Unresectable Liver Cancer
From ESMO Congress 2022:
Camrelizumab plus rivoceranib may significantly extend survival compared with sorafenib for patients with previously untreated unresectable or metastatic hepatocellular carcinoma
Five-Year Findings Confirm Neoadjuvant T-VEC Benefits For Advanced Melanoma Patients
From ESMO Congress 2022:
Patients with resectable stage IIIB–IVM1a melanoma derive a survival benefit from receipt of talimogene laherparepvec treatment before surgery